Collegium Pharmaceutical
COLL
177 hedge funds and large institutions have $843M invested in Collegium Pharmaceutical in 2023 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 63 increasing their positions, 70 reducing their positions, and 36 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
1.19% less ownership
Funds ownership: 114.62% → 113.43% (-1.2%)
10% less capital invested
Capital invested by funds: $937M → $843M (-$93.3M)
10% less repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 70
11% less funds holding
Funds holding: 198 → 177 (-21)
58% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 36
91% less call options, than puts
Call options by funds: $122K | Put options by funds: $1.29M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$15.5M |
| 2 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$7.65M |
| 3 |
BlackRock
New York
|
+$6.05M |
| 4 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$4.68M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$3.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$6.9M |
| 2 |
Millennium Management
New York
|
-$5.53M |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$4.7M |
| 4 |
Janus Henderson Group
London,
|
-$4.59M |
| 5 |
IECM
Intrinsic Edge Capital Management
Chicago,
Illinois
|
-$3.88M |
COLL Hedge Fund Activity: Q2 2023 in Review
177 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q2 2023, worth a combined $843M — down 10% from $937M a quarter earlier.
Sellers outnumbered buyers: 36 funds closed out of COLL and 15 opened new positions — a net loss of 21 holders — while 70 trimmed existing stakes and 63 added.
The largest buyer was Victory Capital Management, adding an estimated $15.5M. The largest seller was Cambridge Investment Research Advisors, cutting an estimated $6.9M.
- 177 institutional investors held Collegium Pharmaceutical (COLL) as of Q2 2023, down from 198 in Q1 2023.
- Funds reported $843M of Collegium Pharmaceutical stock for Q2 2023, down 10% quarter-over-quarter.
- 15 funds opened new Collegium Pharmaceutical positions in Q2 2023 and 36 closed out, a net change of -21 holders.
- The largest Collegium Pharmaceutical buyer in Q2 2023 was Victory Capital Management, an estimated $15.5M added.
- The largest Collegium Pharmaceutical seller in Q2 2023 was Cambridge Investment Research Advisors, an estimated $6.9M sold.
Based on aggregated 13F filings for Q2 2023.